Suche   Â
DGAP-News: Apricus Biosciences Completes Acquisition of Topotarget USA, Inc.
ID: 546890
(firmenpresse) - Apricus Biosciences, Inc.
29.12.2011 18:30
---------------------------------------------------------------------------
To Rename the Newly Acquired Company, Apricus Pharmaceuticals USA, Inc.
SAN DIEGO, Dec. 29, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
('Apricus Bio') (Nasdaq:APRI) (http://www.apricusbio.com) announced today the
closing of its acquisition of Topotarget USA, Inc., a subsidiary of Topotarget
A/S, a Danish company listed on the Copenhagen exchange.
Pursuant to the closing, Topotarget USA, Inc., based in Rockaway, New Jersey,
will become a wholly-owned subsidiary of Apricus Bio. The Company also
announced that it will change the name of Topotarget USA, Inc. to Apricus
Pharmaceuticals USA, Inc. ('Apricus Pharma').
'We are extremely pleased with the acquisition of Totect(r), a valuable product
for the treatment of anthracycline extravasation, the leakage of chemotherapy
into the tissue of cancer patients,' said Dr. Bassam Damaj, Chairman, President
and CEO of Apricus Bio. 'We are looking forward to expanding the territory of
Totect(r) to Canada and Latin America, in addition to acquiring additional
products in the U.S. and abroad to expand the breadth of our oncology and
related product portfolio for Apricus Pharma. Combined with Vitaros(r) and other
products based on our NexACT(r) technology portfolio, we are looking to expand
the breadth of our group product offerings internationally and increase our
worldwide product revenue.'
About Totect(r) and the Anthracycline Extravasation Market
Totect(r), or Dexrazoxane HCl, is used to treat anthracycline extravasation,
which is the leaking of chemotherapy from the veins of cancer patients into
tissues and other areas of the body. Anthracyclines are among the most used
chemotherapy drugs to treat cancer. There are over 500,000 anthracycline
infusions in the U.S. every year and if an extravasation that occurs following
an anthracycline infusion is left untreated, patients with this condition may
risk serious infection, tissue necrosis, or in some cases death. It is
estimated that in the U.S., there are approximately 3,500 cancer centers that
provide chemotherapy treatments where anthracyclines are administered. Totect(r),
has been on the market in the U.S. since 2007. More information on Totect(r) can
be found on www.totect.com.
About Apricus Biosciences, Inc.
Apricus Bio is a San Diego-based, revenue-generating, specialty pharmaceutical
company, with commercial products and a broad pipeline across numerous
therapeutic classes.
Revenues and growth are driven from the sales of the Company's commercial
products through its Apricus Pharmaceuticals USA, Inc. and NexMed (USA), Inc.
subsidiaries and through out-licensing in certain territories of its product
pipeline and NexACT(r) technology. Apricus Bio's current pipeline includes
Vitaros(r), approved in Canada for the treatment of erectile dysfunction, Totect(r)
the only drug approved in the U.S. for the treatment of anthracycline
extravasation, as well as compounds in development from pre-clinical through
pre-registration, currently focused on Sexual Dysfunction, Oncology,
Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Consumer
Healthcare.
The Company also expects to develop and/or acquire and then bring to market
additional pharmaceutical products in areas of care that will benefit patient
needs worldwide.
For further information on Apricus Bio, visit http://www.apricusbio.com, and
for information on its subsidiary please visit http://www.nexmedusa.com. You
can also receive information at http://twitter.com/apricusbio and
http://facebook.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to receive issued patents on its
NexACT(r) technology and products, develop such patented technology into product
candidates, have its Rx Division products and product candidates such as
Vitaros(r) approved by relevant regulatory authorities and its Consumer
Healthcare Division products either approved or cleared by relevant regulatory
authorities or be in compliance with appropriate regulatory requirements, to
successfully manufacture and commercialize such Rx Division products as Totect(r)
for the treatment of anthracycline extravasation and Vitaros(r) in the U.S.,
Canada, and in other countries along with its Consumer Healthcare Division
products and product candidates and to achieve its other development,
commercialization and financial goals. Readers are cautioned not to place undue
reliance on these forward-looking statements as actual results could differ
materially from the forward-looking statements contained herein. Readers are
urged to read the risk factors set forth in the Company's most recent annual
report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other
filings made with the SEC. Copies of these reports are available from the SEC's
website or without charge from the Company.
Apricus Biosciences, Inc.
Edward Cox, V.P.
Corporate Development&Investor Relations, Apricus Bio, Inc.
(858) 848-4249
ecox(at)apricusbio.com
Apricus Bio Investor Relations
Paula Schwartz
Rx Communications Group, LLC
(917) 322-2216
pschwartz(at)rxir.com
News Source: NASDAQ OMX
29.12.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Apricus Biosciences, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
  
  
  
Datum: 29.12.2011 - 18:30 Uhr
Sprache: Deutsch
News-ID 546890
Anzahl Zeichen: 7350
Kontakt-Informationen:
Kategorie:
Wirtschaft (allg.)
Diese Pressemitteilung wurde bisher 0 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Apricus Biosciences Completes Acquisition of Topotarget USA, Inc."
steht unter der journalistisch-redaktionellen Verantwortung von
Apricus Biosciences, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).